SK312004A3 - Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions - Google Patents
Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions Download PDFInfo
- Publication number
- SK312004A3 SK312004A3 SK31-2004A SK312004A SK312004A3 SK 312004 A3 SK312004 A3 SK 312004A3 SK 312004 A SK312004 A SK 312004A SK 312004 A3 SK312004 A3 SK 312004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- treatment
- disease
- pharmaceutically acceptable
- diseases
- acid addition
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 230000003920 cognitive function Effects 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 19
- 230000007423 decrease Effects 0.000 title abstract 2
- 229950011405 deramciclane Drugs 0.000 title description 11
- QOBGWWQAMAPULA-RLLQIKCJSA-N n,n-dimethyl-2-[[(1r,3s,4r)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine Chemical compound C1([C@@]2([C@]3(C)CC[C@@H](C3(C)C)C2)OCCN(C)C)=CC=CC=C1 QOBGWWQAMAPULA-RLLQIKCJSA-N 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 230000003340 mental effect Effects 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- 230000006735 deficit Effects 0.000 claims description 16
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 230000006806 disease prevention Effects 0.000 claims description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 206010039966 Senile dementia Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- JSZIERUELMKQRO-WLHGVMLRSA-N (e)-but-2-enedioic acid;heptane Chemical compound CCCCCCC.OC(=O)\C=C\C(O)=O JSZIERUELMKQRO-WLHGVMLRSA-N 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 28
- 238000012360 testing method Methods 0.000 description 10
- 230000035939 shock Effects 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000000949 anxiolytic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 230000007787 long-term memory Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 229920005372 Plexiglas® Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical class C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- -1 hydrogen halides Chemical class 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0103017A HUP0103017A3 (en) | 2001-07-18 | 2001-07-18 | Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use |
| PCT/HU2002/000069 WO2003007926A2 (en) | 2001-07-18 | 2002-07-18 | Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK312004A3 true SK312004A3 (en) | 2004-06-08 |
Family
ID=90001562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK31-2004A SK312004A3 (en) | 2001-07-18 | 2002-07-18 | Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040171696A1 (ja) |
| EP (1) | EP1408940B1 (ja) |
| JP (1) | JP2004537548A (ja) |
| KR (1) | KR20040017326A (ja) |
| CN (1) | CN1545410A (ja) |
| AT (1) | ATE408403T1 (ja) |
| CA (1) | CA2453834A1 (ja) |
| CZ (1) | CZ200460A3 (ja) |
| DE (1) | DE60228968D1 (ja) |
| EA (1) | EA006897B1 (ja) |
| HU (1) | HUP0103017A3 (ja) |
| IL (1) | IL159841A0 (ja) |
| PL (1) | PL365258A1 (ja) |
| RS (1) | RS4904A (ja) |
| SK (1) | SK312004A3 (ja) |
| UA (1) | UA78714C2 (ja) |
| WO (1) | WO2003007926A2 (ja) |
| ZA (1) | ZA200400481B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0301537A3 (en) * | 2003-06-03 | 2005-07-28 | Egis Gyogyszergyar Nyilvanosan | Deramcyclane fumarate tablets and process for producing them |
| HUP0301906A3 (en) * | 2003-06-23 | 2006-03-28 | Egis Gyogyszergyar Nyilvanosan | Use of bicyclo[2.2.1]heptane derivatives for producing of pharmaceutical compositions having neuroprotectiv activity |
| EP1500391A1 (en) * | 2003-07-24 | 2005-01-26 | Neuro3D | Therapeutic use of bicycloheptane derivatives |
| CZ2006623A3 (cs) * | 2004-03-12 | 2007-01-24 | Egis Gyogyszergyár Nyrt. | Kombinace deramciklanu a opioidů jako analgetik |
| US20080021016A1 (en) * | 2004-03-12 | 2008-01-24 | Levay Gyoergy | Combined Pharmaceutical Composition for the Inhibition of the Decline of Cognitive Functions |
| KR101642113B1 (ko) | 2014-10-08 | 2016-07-25 | 원광대학교산학협력단 | 퇴행성 뇌질환을 예방, 개선 또는 치료하는 유황의 법제 방법 및 상기 방법으로 법제된 유황 |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU179164B (en) * | 1979-12-14 | 1982-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing cycloalkyl-ethers of alkanolamines |
| HU226061B1 (en) * | 1996-10-17 | 2008-04-28 | Egis Gyogyszergyar Nyilvanosan | 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation |
| HU227114B1 (en) * | 1999-05-11 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
-
2001
- 2001-07-18 HU HU0103017A patent/HUP0103017A3/hu unknown
-
2002
- 2002-07-18 SK SK31-2004A patent/SK312004A3/sk not_active Application Discontinuation
- 2002-07-18 CA CA002453834A patent/CA2453834A1/en not_active Abandoned
- 2002-07-18 CN CNA028163729A patent/CN1545410A/zh active Pending
- 2002-07-18 WO PCT/HU2002/000069 patent/WO2003007926A2/en active IP Right Grant
- 2002-07-18 IL IL15984102A patent/IL159841A0/xx unknown
- 2002-07-18 CZ CZ200460A patent/CZ200460A3/cs unknown
- 2002-07-18 RS YU4904A patent/RS4904A/sr unknown
- 2002-07-18 AT AT02745700T patent/ATE408403T1/de not_active IP Right Cessation
- 2002-07-18 EP EP02745700A patent/EP1408940B1/en not_active Expired - Lifetime
- 2002-07-18 US US10/483,808 patent/US20040171696A1/en not_active Abandoned
- 2002-07-18 EA EA200400192A patent/EA006897B1/ru not_active IP Right Cessation
- 2002-07-18 DE DE60228968T patent/DE60228968D1/de not_active Expired - Fee Related
- 2002-07-18 PL PL02365258A patent/PL365258A1/xx not_active Application Discontinuation
- 2002-07-18 JP JP2003513535A patent/JP2004537548A/ja active Pending
- 2002-07-18 KR KR10-2004-7000792A patent/KR20040017326A/ko active IP Right Grant
- 2002-07-18 UA UA2004021167A patent/UA78714C2/uk unknown
-
2004
- 2004-01-22 ZA ZA200400481A patent/ZA200400481B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60228968D1 (de) | 2008-10-30 |
| HUP0103017A2 (hu) | 2003-07-28 |
| HUP0103017D0 (en) | 2001-10-28 |
| RS4904A (en) | 2006-10-27 |
| UA78714C2 (en) | 2007-04-25 |
| EP1408940A2 (en) | 2004-04-21 |
| CN1545410A (zh) | 2004-11-10 |
| US20040171696A1 (en) | 2004-09-02 |
| CA2453834A1 (en) | 2003-01-30 |
| IL159841A0 (en) | 2004-06-20 |
| HUP0103017A3 (en) | 2004-05-28 |
| EA200400192A1 (ru) | 2004-06-24 |
| WO2003007926A3 (en) | 2003-09-18 |
| CZ200460A3 (cs) | 2004-05-12 |
| ATE408403T1 (de) | 2008-10-15 |
| WO2003007926A2 (en) | 2003-01-30 |
| KR20040017326A (ko) | 2004-02-26 |
| PL365258A1 (en) | 2004-12-27 |
| EA006897B1 (ru) | 2006-04-28 |
| ZA200400481B (en) | 2005-01-24 |
| EP1408940B1 (en) | 2008-09-17 |
| JP2004537548A (ja) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6287597B1 (en) | Antihistaminic/decongestant compositions | |
| KR20140038378A (ko) | 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료 | |
| HU202108B (en) | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol | |
| US6417206B1 (en) | Antitussive/antihist aminic/decongestant compositions | |
| CN116940362A (zh) | 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性 | |
| SK312004A3 (en) | Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions | |
| EP1014974A1 (en) | Treatment of schizophrenia and psychosis | |
| AU608922B2 (en) | Method for the treatment of anxiety | |
| AU2020271363A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| AU2012258339A1 (en) | New combination between 4-{3-[Cis-Hexahydrocyclopenta[c]Pyrrol-2(1H)-yl]Propoxy}Benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it | |
| ITMI951417A1 (it) | Composizioni farmaceutiche e procedimento per la loro preparazione | |
| US6962921B2 (en) | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | |
| CZ20023025A3 (cs) | Léčba chorob vztahujících se k serotonergnímu systému | |
| US20010049394A1 (en) | Treatment of disorders relating to the serotonergic system | |
| US20230000859A1 (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| SK17142000A3 (sk) | Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety | |
| AU2002317412A1 (en) | Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions | |
| EP0621781A1 (en) | Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses | |
| WO2024050028A1 (en) | Methods and compositions for treating acute stress disorder | |
| EA047219B1 (ru) | Способы лечения поведенческих и психологических симптомов у пациентов с деменцией | |
| CZ284061B6 (cs) | Použití isethionátu 3,5-diamino-6-(2,3-dichlorfenyl)-1,2,4-triazinu pro výrobu léčiva pro ošetřování a prevenci závislosti, tolerance a citlivosti k drogám |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |